Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 1, pp 275–281 | Cite as

Intrahepatic Recurrence Patterns Predict Survival After Resection of Colorectal Liver Metastases

  • Andrew J. Lee
  • Evelyne M. Loyer
  • Hyunseon C. Kang
  • Thomas A. Aloia
  • Ching-Wei D. Tzeng
  • Jean-Nicolas Vauthey
  • Yun Shin ChunEmail author
Hepatobiliary Tumors
  • 137 Downloads

Abstract

Background

After resection of colorectal liver metastases (CLM), up to 40% of patients will develop intrahepatic recurrence. This study aims to identify patterns of intrahepatic recurrence and their impact on survival after preoperative chemotherapy and CLM resection.

Methods

A retrospective review was performed of patients developing intrahepatic recurrence after CLM resection following preoperative chemotherapy. Prechemotherapy, preoperative, and postoperative computed tomography scans were reviewed. Recurrences were classified as in situ, de novo, or both in situ and de novo. Median follow-up was 42 months (range 2–144 months).

Results

Among 223 patients meeting study criteria, intrahepatic recurrence was identified a median of 9 months after hepatectomy. Isolated de novo or in situ recurrence developed in 105 (47%) and 86 (39%) patients, respectively. Thirty-two patients (14%) developed both in situ and de novo recurrence, which was associated with significantly lower median overall survival of 33 months compared with 49 and 45 months with isolated in situ or de novo recurrence, respectively (p = 0.048). Among 118 patients (53%) who developed in situ recurrence as a component of disease relapse, recurrences resulted from disappearing or missed liver metastases in 47 patients (40%).

Conclusions

An intrahepatic recurrence pattern of both in situ and de novo metastases after CLM resection following preoperative chemotherapy predicts significantly worse overall survival compared with isolated in situ or de novo recurrence.

Notes

Funding

This research was supported in part by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant, CA016672.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25 (discussion 817–25).CrossRefGoogle Scholar
  3. 3.
    Wicherts DA, de Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100(6):808–18.CrossRefGoogle Scholar
  4. 4.
    D’Angelica M, Kornprat P, Gonen M, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18(4):1096–103.CrossRefGoogle Scholar
  5. 5.
    Hill CR, Chagpar RB, Callender GG, et al. Recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol. 2012;19(1):139–44.CrossRefGoogle Scholar
  6. 6.
    Couinaud C. Liver lobes and segments: notes on the anatomical architecture and surgery of the liver. Presse Med. 1954;62(33):709–12.Google Scholar
  7. 7.
    Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008;371(9617):963–5.CrossRefGoogle Scholar
  8. 8.
    Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1261–8.CrossRefGoogle Scholar
  9. 9.
    Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–44.CrossRefGoogle Scholar
  10. 10.
    Shindoh J, Tzeng CW, Aloia TA, et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg. 2013;100(13):1777–83.CrossRefGoogle Scholar
  11. 11.
    Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29(8):1083–90.CrossRefGoogle Scholar
  12. 12.
    de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–8.Google Scholar
  13. 13.
    Bischof DA, Clary BM, Maithel SK, Pawlik TM. Surgical management of disappearing colorectal liver metastases. Br J Surg. 2013;100(11):1414–20.CrossRefGoogle Scholar
  14. 14.
    Owen JW, Fowler KJ, Doyle MB, Saad NE, Linehan DC, Chapman WC. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB (Oxford). 2016;18(3):296–303.CrossRefGoogle Scholar
  15. 15.
    Que FG, Nagorney DM. Resection of ‘recurrent’ colorectal metastases to the liver. Br J Surg. 1994;81(2):255–8.CrossRefGoogle Scholar
  16. 16.
    Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22 (discussion 714–22).CrossRefGoogle Scholar
  17. 17.
    Sadot E, Groot Koerkamp B, Leal JN, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015;262(3):476–85 (discussion 475–83).CrossRefGoogle Scholar
  18. 18.
    Brouquet A, Vauthey JN, Badgwell BD, et al. Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation. Br J Surg. 2011;98(7):1003–9.CrossRefGoogle Scholar
  19. 19.
    Chun YS, Vauthey JN. Local therapy for colorectal liver metastases: establishing today’s level of evidence and defining tomorrow’s roadmap. J Natl Cancer Inst. 2017.  https://doi.org/10.1093/jnci/djx018.Google Scholar
  20. 20.
    Odisio BC, Yamashita S, Frota L, et al. Planned treatment of advanced metastatic disease with completion ablation after hepatic resection. J Gastrointest Surg. 2017;21(4):628–35.CrossRefGoogle Scholar
  21. 21.
    Angliviel B, Benoist S, Penna C, et al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol. 2009;16(5):1247–53.CrossRefGoogle Scholar
  22. 22.
    Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010;116(6):1502–9.CrossRefGoogle Scholar
  23. 23.
    Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352(7):734–5.CrossRefGoogle Scholar
  24. 24.
    Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002;20(6):1499–505.Google Scholar
  25. 25.
    Hallet J, Sa Cunha A, Adam R, et al. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br J Surg. 2016;103(10):1366–76.CrossRefGoogle Scholar
  26. 26.
    Andreou A, Brouquet A, Abdalla EK, Aloia TA, Curley SA, Vauthey JN. Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford). 2011;13(11):774–82.CrossRefGoogle Scholar
  27. 27.
    Denbo JW, Yamashita S, Passot G, et al. RAS mutation is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg. 2017;21(1):68–77.CrossRefGoogle Scholar
  28. 28.
    Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018.  https://doi.org/10.1001/jamasurg.2018.0996.Google Scholar
  29. 29.
    Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014;120(24):3965–71.CrossRefGoogle Scholar
  30. 30.
    Park MJ, Hong N, Han K, et al. Use of imaging to predict complete response of colorectal liver metastases after chemotherapy: MR imaging versus CT imaging. Radiology. 2017;284(2):423–31.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Andrew J. Lee
    • 1
  • Evelyne M. Loyer
    • 2
  • Hyunseon C. Kang
    • 2
  • Thomas A. Aloia
    • 1
  • Ching-Wei D. Tzeng
    • 1
  • Jean-Nicolas Vauthey
    • 1
  • Yun Shin Chun
    • 1
    Email author
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Diagnostic RadiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations